Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure~* No contra-indication to stop (according to label) anti-hypertensive treatment(s) at screening~* Mild-to-moderate essential hypertension with or without ongoing anti-hypertensive treatment(s):~  -- Mean (of 5 measurements) sitting diastolic blood pressure (SiDBP) ≥ 90 to \< 110 mmHg measured by office blood pressure measurements (OBPM).~* Women of childbearing potential must have a negative pregnancy test and use of reliable methods of contraception~Exclusion Criteria:~* Severe hypertension (grade 3): mean sitting systolic/diastolic BP (SiSBP/SiDBP; measured by OBPM) ≥ 180/110 mmHg, respectively.~* Secondary hypertension~* Known hypertensive retinopathy greater than Keith-Wagener Grade 2~* Myocardial infarction, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within 12 months prior to randomization~* Unstable angina within 6 months prior to randomization~* Heart failure New York Heart Association class III and IV~* Valvular defects (such as severe aortic or mitral valve disease) and/or hemodynamically relevant rhythm disturbances~* Clinical evidence of cerebrovascular insufficiency or a cerebrovascular accident within 6 months prior to randomization.~* Subjects working night shifts~* Body mass index \< 20 kg/m2 or \> 40 kg/m2~* Treatment with any medication which may affect BP (e.g., treatment of psychiatric diseases, ophthalmic preparations)~* Treatment with strong cytochrome P450 3A4 (CYP3A4) isoenzyme inhibitors or inducers~* Treatment with guanethidine and/or mineralocorticoid receptor antagonists within 1 month prior to Screening (Visit 1)~* Treatment with another investigational treatment within 1 month prior to Screening (Visit 1)~* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
- Aprocitentan 5 mg (Type: EXPERIMENTAL): After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
- Aprocitentan 10 mg (Type: EXPERIMENTAL): After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
- Aprocitentan 25 mg (Type: EXPERIMENTAL): After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
- Aprocitentan 50 mg (Type: EXPERIMENTAL): After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
- Lisinopril 20 mg (Type: ACTIVE_COMPARATOR): After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).